uniQure (QURE) Announces Closing of CSL Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
uniQure BV (QURE) Risk/Reward 'Heavily Skewed To The Upside' - Raymond James
May 6, 2021 9:44 AM EDTRaymond James analyst Danielle Brill reiterated a Strong Buy rating and $75.00 price target on uniQure BV (NASDAQ: QURE) after announcing the licensing agreement with CSL Behring for its HemB gene therapy (etranacogene dezaparvovec (EtranaDez)) has closed.
"In our view, the hemophilia-B gene... More
